This is an extremely important, and practical question, which, unfortunately, we have very limited data on. Clearly, more study is needed here so that we can develop more carefully tailored therapies for our patients. However, for now, my approach is primarily based on the timing of metastatic disea...

This is also a very clinically relevant question, for which there are no data to guide the optimal approach. As with the previous question, I think all of us would benefit from other perspectives. I'm not aware of any data in any solid tumor malignancy that identifies the optimal immunotherapy or n...

This is a challenging scenario and in general, I would still favor use of chemo+immunotherapy in patients with Her2 NEG disease who have CPS 5 or higher or are dMMR, even if they received (or are currently receiving) adjuvant nivolumab, in the absence of an available first line clinical trial option...